-
Mashup Score: 0Future Treatment Landscape for R/R MM with CAR-T - 1 month(s) ago
Binod Dhakal, MD, explores how CAR-T therapy may impact the future treatment landscape for R/R MM, including current unmet needs and clinical pearls for community oncologists treating patients with R/R MM.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 0Clinical Perspectives on CAR-T in R/R MM - 1 month(s) ago
Binod Dhakal, MD, shares clinical perspectives on using CAR-T therapy in R/R MM, highlighting the implications of the latest data for community oncologists and their patients.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Binod Dhakal, MD, shares clinical perspectives on using CAR T-cell therapy in #RRMM, highlighting the implications of the latest data for community oncologists and their patients. @MedicalCollege @bhemato https://t.co/JJ3Uonc0S4
-
-
Mashup Score: 0Standard of Care for R/R Multiple Myeloma - 1 month(s) ago
Binod Dhakal, MD, discusses the current standard of care for R/R MM, highlighting how treatment decision-making changes for patients who are refractory to lenalidomide and/or bortezomib.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Binod Dhakal, MD, discusses the current standard of care for #RRMM and discusses decision-making and treatments for patients who are refractory to lenalidomide and/or bortezomib. @MedicalCollege https://t.co/uUs8s2NOER
-
-
Mashup Score: 1
Company will initiate Phase 1 study of CLN-619 for relapsed or refractory multiple myeloma, first MICA/B antibody clinical study in hematologic…
Source: www.globenewswire.comCategories: General Medicine News, Onc News and JournalsTweet-
🚨 NEWS 🚨 @US_FDA clears an Investigational New Drug application for a phase I dose-escalation and dose-expansion trial of CLN-619, an IgG1 monoclonal antibody that binds to stress-induced MICE and MICB ligands, for the treatment of #RRMM. Read more: https://t.co/cq1U9JfTC8… https://t.co/d8ygOYrSnR https://t.co/4N0MQbv6aD
-
-
Mashup Score: 2
In the second article of a 2-part series, Sumit Madan, MD, talked about the manageable toxicity profile with the triplet therapy selinexor (Xpovio), bortezomib, and dexamethasone and how dose reductions led to tolerable outcomes in patients with relapsed/refractory multiple myeloma.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet-
Sumit Madan, MD, talked about the manageable toxicity profile with the triplet therapy selinexor, bortezomib, and dexamethasone and how dose reductions led to tolerable outcomes in patients with #RRMM. @MDAndersonNews https://t.co/ED2jKrzReh
-
-
Mashup Score: 0
According to data presented at IMS 2023, a real-world analysis showed that teclistamab demonstrated comparable efficacy to the results observed in the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Findings from a real-world study of patients with #RRMM showed that teclistamab had similar efficacy to what was seen in the phase 2 Majes-TEC-1 trial. #IMS23 | @DanaFarber https://t.co/kcVWZZFZeW
-
-
Mashup Score: 1LINKER-MM1 Supports Development of Linvoseltamab in Multiple Myeloma - 8 month(s) ago
In an interview with Targeted Oncology, Hans C. Lee, MD, discussed the safety and efficacy results of the phase 2 LINKER-MM1 study.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
In an interview with Targeted Oncology, Hans C. Lee, MD, discussed the safety and efficacy results of the phase 2 LINKER-MM1 study for patients with relapsed/refractory multiple myeloma. #mmsm #RRMM | @MDAndersonNews https://t.co/9h2vVepANB https://t.co/b0rntHF0xP
-
-
Mashup Score: 0FDA Grants Accelerated Approval to Talquetamab for RRMM - 8 month(s) ago
Data from the phase 2 MonumenTAL-1 study support the accelerated approval of talquetamab in patients with relapsed/refractory who have received at least 4 prior lines of therapy.
Source: www.targetedonc.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
ICYMI: Talquetamab-tgvs is approved for patients with #RRMM under accelerated approval based on response rate and durability of response. https://t.co/XxtDoyFVx4
-
-
Mashup Score: 0Roundtable Roundup: Multiple Myeloma - 10 month(s) ago
In separate, live virtual events, Jonathan L. Kaufman, MD, and Morie A. Gertz, MD, MACP, discussed concerns about using chimeric antigen receptor T-cell therapy for a patient with relapsed/refractory multiple myeloma who is experiencing rapid disease progression.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Jonathan L. Kaufman, MD, & Morie A. Gertz, MD, MACP, discussed concerns about using CAR T-cell therapy for a patient with #RRMM who is experiencing rapid disease progression. #mmsm | @WinshipAtEmory @MayoCancerCare https://t.co/96eqGA0bvF
-
-
Mashup Score: 1
In patients with relapsed/refractory multiple myeloma who were previously treated with lenalidomide, the combination of daratumumab, ixazomib, and dexamethasone led to improved overall response rates.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#Daratumumab with ixazomib and dexamethasone led to rapid response rates in patients with #RRMM who were pretreated with lenalidomide, according to the findings from the phase 2 DARIA trial. #EHA2023 #mmsm https://t.co/pUKS1qkx1x
-
To conclude his conversation, Binod Dhakal, MD, explores how CAR T-cell therapy may impact the future treatment landscape for #RRMM. @bhemato @MedicalCollege https://t.co/2fd3cNh77X